Margaret L. Thomas

Halifax, NS B3H4R2, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

DNA Methylation Predicts the Response of Triple-Negative Breast Cancers to All-Trans Retinoic Acid.

DNA Methylation Predicts the Response of Triple-Negative Breast Cancers to All-Trans Retinoic Acid.

Journal: Cancers
Published: September 21, 2018

Regulation of cell surface protease receptor S100A10 by retinoic acid therapy in acute promyelocytic leukemia (APL)☆.

Regulation of cell surface protease receptor S100A10 by retinoic acid therapy in acute promyelocytic leukemia (APL)☆.

Journal: Cell death & disease
Published: May 27, 2018

Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum.

Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum.

Journal: Cancers
Published: February 14, 2018

Profiling of the transcriptional response to all-trans retinoic acid in breast cancer cells reveals RARE-independent mechanisms of gene expression.

Profiling of the transcriptional response to all-trans retinoic acid in breast cancer cells reveals RARE-independent mechanisms of gene expression.

Journal: Scientific reports
Published: September 06, 2017

Epigenetic Silencing of TAP1 in Aldefluor+ Breast Cancer Stem Cells Contributes to Their Enhanced Immune Evasion.

Epigenetic Silencing of TAP1 in Aldefluor+ Breast Cancer Stem Cells Contributes to Their Enhanced Immune Evasion.

Journal: Stem cells (Dayton, Ohio)
Published: July 15, 2017

Hide-and-seek: the interplay between cancer stem cells and the immune system.

Hide-and-seek: the interplay between cancer stem cells and the immune system.

Journal: Carcinogenesis
Published: June 04, 2016

Citral reduces breast tumor growth by inhibiting the cancer stem cell marker ALDH1A3.

Citral reduces breast tumor growth by inhibiting the cancer stem cell marker ALDH1A3.

Journal: Molecular oncology
Published: April 27, 2016

Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1.

Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1.

Journal: Oncotarget
Published: March 30, 2016
Showing 1-8 of 8

Last Updated: 09/26/2026